Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Amy Brookman

Physician Assistant, Surgical Arlington, WA Physician Assistant

NPI 1871106187 CMS profile 11309729

328 S Stillaguamish Ave, Arlington, WA 98223

Open in the dashboard

General payments

$3,670

141 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amy Brookman of Arlington, WA is reported in the CMS Open Payments database as having received $3,670 across 141 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $423 12
2024 General $377 12
2023 General $890 34
2022 General $1,980 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amy Brookman
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Amy Brookman were reported at $423. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Amy Brookman Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $111 $36–$285 $132
2022 $1,980 $126 $44–$350 $149
2023 $890 $137 $47–$355 $160
2024 $377 $146 $49–$384 $164
2025 $423 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AstraZeneca Pharmaceuticals LP $949 31 payments
  2. Genzyme Corporation $451 19 payments
  3. CSL Behring $358 15 payments
  4. GlaxoSmithKline, LLC. $343 16 payments
  5. Regeneron Healthcare Solutions, Inc. $258 4 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $255 12 payments
  7. ADMA BioManufacturing LLC $214 3 payments
  8. Genentech USA, Inc. $184 12 payments
  9. Grifols USA, LLC $153 7 payments
  10. BioCryst US Sales Co., LLC $148 5 payments
  11. Other $359 17 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $3,472 139 payments
  2. Education $100 1 payment
  3. Consulting Fee $98 1 payment
Products named General payments · program years 2022–2025
  1. DUPIXENT Immunology $580 24 payments
  2. FASENRA $453 17 payments
  3. Haegarda $241 10 payments
  4. TRELEGY ELLIPTA $176 9 payments
  5. NUCALA $167 7 payments
  6. BREZTRI $162 3 payments
  7. DUPIXENT Inflammation And Immunology $159 3 payments
  8. Xembify $153 7 payments
  9. Orladeyo $148 5 payments
  10. Xolair $146 10 payments
  11. Other $1,224 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

337

Median for Physician Assistant: 241

Drug cost

$24,688

Median for Physician Assistant: $4,110

Branded share of claims

24.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 17 $10,643
Epinephrine Generic 31 $7,873
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 13 $2,155
Montelukast Sodium Generic 91 $1,282
Azelastine Hcl Generic 67 $1,056
Albuterol Sulfate Hfa Albuterol Sulfate Brand 25 $479
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 16 $384
Levocetirizine Dihydrochloride Generic 25 $325
Fluticasone Propionate Generic 28 $278
Mupirocin Generic 13 $115

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$19,938

Medicare's payments for the services billed

Medicare patients

78

Average age 73

Services billed

1,566

51 women, 27 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 42%
Ischemic heart disease 21%
Atrial fibrillation 19%
Osteoporosis 18%
Diabetes 15%
Chronic kidney disease 15%
Depression 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FASENRA
  • AstraZeneca Pharmaceuticals LP $209
$209 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $118
  • GENZYME CORPORATION $28
$146 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

141 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Surgical in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record